Spyre Therapeutics, Inc.

Spyre Therapeutics is a clinical-stage biotechnology company developing monoclonal antibody therapies for inflammatory bowel disease and rheumatic diseases. The company's pipeline includes SPY001, a humanized anti-α4β7 integrin antibody in Phase 2 development for ulcerative colitis and Crohn's disease, and SPY002 and SPY072, anti-TL1A monoclonal antibodies also in clinical development. SPY003, targeting interleukin-23, is similarly in Phase 2 clinical trials. Beyond single agents, Spyre is advancing combination programs including SPY120 (anti-α4β7 plus anti-TL1A), SPY130 (anti-α4β7 plus anti-IL-23), and SPY230 (anti-TL1A plus anti-IL-23).

The company was incorporated in Delaware in 2013 and is headquartered in Waltham, Massachusetts. As a clinical-stage organization, Spyre does not generate product revenue and operates in the development phase. The company has 102 full-time employees and is listed on the Nasdaq exchange. Spyre underwent a corporate restructuring and name change in November 2023, transitioning from its previous identity as Aeglea BioTherapeutics, Inc. to focus exclusively on its immunology pipeline.